Chou William 4

What Happened
William Chou, President, CEO and a director of Passage BIO, was granted 58,000 derivative securities (reported as an award/acquisition) on March 16, 2026. The filing reports an acquisition price of $0.00 for the derivative award (total reported value $0). This was an award/grant (not an open-market purchase or sale) and is compensation-related rather than a cash purchase.

Key Details

• Transaction date: 2026-03-16; Form 4 filed: 2026-03-18 (filing appears timely).
• Instrument: Derivative securities reported as an Award/Grant (code A).
• Quantity: 58,000 shares (derivative/option-style award). Reported per-share acquisition price: $0.00; total reported value: $0.
• Vesting: Footnote states vesting as to 1/48 of the total shares monthly beginning April 16, 2026 until fully vested, subject to continued service.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• No immediate exercise or sale reported in this filing.

Context
This is a typical executive compensation grant (an award of derivative securities) rather than a market purchase or sale. The award vests monthly over four years contingent on continued service; there is no indication here of an immediate cashless exercise or disposition. Such grants do not, by themselves, indicate whether the insider will later exercise or sell shares.